News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
692,673 Results
Type
Article (39438)
Company Profile (247)
Press Release (652988)
Section
Business (204076)
Career Advice (2007)
Deals (35423)
Drug Delivery (94)
Drug Development (80965)
Employer Resources (169)
FDA (16145)
Job Trends (14833)
News (344986)
Policy (32494)
Tag
Academia (2535)
Alliances (49347)
Alzheimer's disease (1316)
Approvals (16129)
Artificial intelligence (200)
Bankruptcy (357)
Best Places to Work (11638)
Biotechnology (175)
Breast cancer (227)
Cancer (1718)
Cardiovascular disease (128)
Career advice (1671)
CAR-T (121)
Cell therapy (354)
Clinical research (65261)
Collaboration (659)
Compensation (370)
COVID-19 (2563)
C-suite (160)
Data (1629)
Diabetes (211)
Diagnostics (6284)
Earnings (85441)
Employer resources (146)
Events (110868)
Executive appointments (564)
FDA (17047)
Funding (602)
Gene therapy (245)
GLP-1 (649)
Government (4358)
Healthcare (18771)
Infectious disease (2674)
Interviews (310)
IPO (16461)
Job creations (3630)
Job search strategy (1422)
Layoffs (437)
Legal (7892)
Lung cancer (260)
Manufacturing (236)
Medical device (13262)
Medtech (13267)
Mergers & acquisitions (19337)
Metabolic disorders (549)
Neuroscience (1717)
NextGen: Class of 2025 (6509)
Non-profit (4475)
Northern California (2090)
Obesity (307)
Opinion (196)
Patents (164)
People (56834)
Phase I (20316)
Phase II (28749)
Phase III (21410)
Pipeline (711)
Postmarket research (2564)
Preclinical (8576)
Radiopharmaceuticals (242)
Rare diseases (321)
Real estate (5898)
Regulatory (21933)
Research institute (2311)
Resumes & cover letters (349)
Southern California (1792)
Startups (3569)
United States (18437)
Vaccines (611)
Weight loss (209)
Date
Today (17)
Last 7 days (593)
Last 30 days (2593)
Last 365 days (34455)
2025 (4429)
2024 (35234)
2023 (40088)
2022 (51179)
2021 (55714)
2020 (54090)
2019 (46545)
2018 (35021)
2017 (32114)
2016 (31483)
2015 (37554)
2014 (31321)
2013 (26347)
2012 (28575)
2011 (29270)
2010 (27337)
Location
Africa (716)
Arizona (211)
Asia (37554)
Australia (6136)
California (4762)
Canada (1715)
China (392)
Colorado (217)
Connecticut (230)
Europe (80422)
Florida (688)
Georgia (165)
Illinois (455)
Indiana (259)
Japan (121)
Maryland (739)
Massachusetts (3602)
Michigan (198)
Minnesota (334)
New Jersey (1347)
New York (1359)
North Carolina (833)
Northern California (2090)
Ohio (173)
Pennsylvania (1098)
South America (1093)
Southern California (1792)
Texas (701)
Utah (143)
Washington State (467)
692,673 Results for "daiichi sankyo inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus will reveal promising mid-stage data for their respective cancer candidates.
December 2, 2024
·
4 min read
·
Tristan Manalac
Press Releases
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
January 31, 2025
·
3 min read
Policy
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.
June 28, 2024
·
1 min read
Approvals
AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners’ Datroway for a related type of breast cancer.
January 28, 2025
·
2 min read
·
Tristan Manalac
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Cancer
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera Pharmaceuticals in April 2024.
February 17, 2025
·
2 min read
·
Tristan Manalac
Lung cancer
After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period
Even before the FDA’s recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate could hit $5.9 billion in 2030. However, the asset faced a series of setbacks in 2024.
January 21, 2025
·
5 min read
·
Nick Paul Taylor
Antibody-drug conjugates
Daiichi Sankyo Admits 2024 Wasn’t ‘Perfect’ but 2025 Is Starting Off With a Bang
The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this month the company has secured an approval for AstraZeneca-partnered Dato-DXd, to be marketed as Datroway.
January 27, 2025
·
5 min read
·
Annalee Armstrong
Business
RevolKa Signed Master Service Agreement with Daiichi Sankyo
RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform signed a master service agreement with Daiichi Sankyo Co., Ltd.
May 27, 2024
·
2 min read
Drug Development
AstraZeneca, Daiichi Sankyo ADC Misses Endpoint in Phase III NSCLC Study
AstraZeneca and Daiichi Sankyo’s investigational antibody-drug conjugate Dato-DXd failed to significantly improve overall survival in non-small cell lung cancer patients versus docetaxel.
May 28, 2024
·
2 min read
·
Tristan Manalac
1 of 69,268
Next
